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Abstract
India is today, one of the top emerging markets in the global pharmaceutical landscape. The sector is highly
knowledge-based and its steady growth is positively affecting the Indian economy. The targets of the global
pharmaceutical companies are always "First to File" with "Right time-first time" approach. A successful
organization always differentiates itself for their process. It works with a vision, leveraging on new technologies
and ideas. In order to have more confidence in data and to understand the analytical development process better,
we need to introduce some orthogonality in our analytical development process like the mass detectors. In order to
automate and fasten the process of method development and transfers, Pharmaceutical scientists uses UPLC’s.
It is an LC system with inbuilt features to support faster method developments like automated solvent/pH/
salt blending and has softwares assisting in method transfers across LC platforms. The adoption of UPLC
methods for various tests by different regulators like US-FDA, EMEA as release methods or alternative methods
and adoption of UPLC by EP and USP in their monographs (NF and MC) clearly reflects the reason for the
increase in trend with respect to its implementation. Hence, Pharmaceutical companies can leverage upon the
new technologies to increase the throughput efficiency and differentiate oneself in this competitive world.
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India is today, one of the top emerging markets in
the global pharmaceutical landscape. The sector
is highly knowledge-based and its steady growth
is positively affecting the Indian economy. The
organized nature of Indian pharmaceutical industry
is attracting several companies that are finding it
viable to increase their operations in the country.
India is expected to be the third-largest global
generic active pharmaceutical ingredient (API)
merchant market in coming years, with 7 per cent
market share approximately.1
The Indian pharmaceutical sector accounts for about
1.4 per cent of the global pharmaceutical industry
in value terms and 10 per cent in volume terms.
The country’s pharmaceutical industry is expected
to expand at a Compounded Annual Growth Rate
(CAGR) of 14.5 % over 2009-2020 to reach US$ 55
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billion. The generics market in India is expected to
grow up to US$ 26.1 billion by 2016 from US$ 11.3
billion in 2011.1
The targets of the global pharmaceutical companies
are always “First to File” with “Right time-first
time” approach. A successful organization always
differentiates itself for their process. It works with
a vision, leveraging on new technologies and ideas.
Apart from the analytical instruments like High
Performance Liquid Chromatography (HPLC), for an
analytical lab to be successful, it requires analytical
aptitude and expertise amongst its scientists. The
technologies like HPLC, Gas Chromatography
(GC), Ultraviolet (UV) and Infrared Radiation (IR)
are conventional and mandatory technologies today
and their usage in analytical laboratories may not be
a differentiating feature anymore.
In order to differentiate from competition and
meeting the targets like “First to file” and “Right
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time-First time”, an organization needs to believe
and invest in new technologies and ideas. Analytical
scientists need to intensify their awareness for new
technologies and solutions that are in the market,
so that they are appropriately utilized. This article
discusses new technologies that can differentiate
your lab from the rest, speed up the development
process and also ensure success.

to introduce some orthogonality in our analytical
development process like the mass detectors. The
new generation of such orthogonal universal mass
detector are designed so that any scientist/analyst
who operates HPLC can use mass detection irrespective
of his prior knowledge about mass spectroscopy. The
usage of such mass detectors during the analytical
development ensures confidence in the data.

In a typical analytical development process, we
have three major requirements - confidence in data,
robustness of the method and speed of development
process.

The challenges in UV/PDA based developments
can be resolved using such orthogonal universal
Mass detectors. The term orthogonal refers to
not only alternative but also techniques which can
verify the correctness of primary technologies.
The new generation Mass detectors are not
spectrophotometers and has been purposefully
designed to enable chromatographers/analysts to
readily incorporate mass detection within a UVPDA chromatographic workflow. The simplicity of
such new generation Mass detectors is such that it
can be handled easily by the chromatographers who
have no Mass Spectrometry (MS) experience.

So, how does one verify that the analytical development
process is on right track? Is implementation of
Quality by Design (Quds) approach in analytical
lab feasible without compromising on time? For
example, in a related substance method development,
we need to address some of the following aspects
such as characterisation of peak, identification of
non chromophoric impurities, tracking/identifying
of peaks during forced degradation studies,
screening and scouting of different chromatographic
conditions as per QbD principles and ensuring
that analytical method indicates stability. Does our
current analytical method development process
cover all these aspects and face no compromise? So,
how does one verify that the analytical development
process is on right track? Is implementation of
Quality by Design (Quds) approach in analytical
lab feasible without compromising on time? For
example, in a related substance method development,
we need to address some of the following aspects
such as characterisation of peak, identification of
non chromophoric impurities, tracking/identifying
of peaks during forced degradation studies,
screening and scouting of different chromatographic
conditions as per QbD principles and ensuring
that analytical method indicates stability. Does our
current analytical method development process
cover all these aspects and face no compromise?
In an analytical development process, we typically
rely on UV-PDA detector as detector of choice
and live with the limitations of the same. In order
to have more confidence in data and to understand
the analytical development process better, we need

Once switched on, the new generation mass
detectors are ready to be used in less than 25 minutes.
They can be controlled through chromatography
software, and hence enabling scientists to do various
tasks like peak tracking and identification, analyzing
non-chromophoric
impurities,
understanding
mass-balance related issues, performing MS finger
printing and confirming peak purity data

Figure 1: Acquity® QDa Mass detector

One of the major limitations of Mass Detector is
its incompatibility with phosphate buffers. Most of
existing pharmacopoeial or non pharmacopoeial
methods have non-MS friendly mobile phase. In
order to analyse such samples with Mass detectors,
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we can utilize the 2D technology to clean-up the
samples. In addition, 2D chromatography can help
to streamline the sample preparation process by
processing smaller sample volumes. Hence, 2D
chromatography also helps to improve the sensitivity,
accuracy and precision of the analysis.

Figure 2: 2-D UPLC

The above descriptions show how orthogonal
detectors and technologies like 2D LC can help
to address the aspect of “confidence in data” in
analytical development process. Now, let us discuss
the role of another innovative technology which
has changed the outlook of industry with respect to
throughput in LC analysis and brought the concept
of “speed” in analysis with “no compromise”, in its
Ultra Performance Liquid Chromatography (UPLC).
In order to automate and fasten the process of
method development and transfers, Pharmaceutical
scientists uses UPLC’s. It is an LC system with inbuilt
features to support faster method developments
like automated solvent/pH/salt blending and has
softwares assisting in method transfers across LC
platforms. UPLC has capabilities of performing
both UPLC and HPLC applications. This flexibility
has translated UPLC H-Class technology into one
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of the best example for “Future-proof ” investment
in Pharmaceutical industry.
Following QbD approach during analytical method
development process was emphasized by US-FDA
in their latest guidance on “Analytical Procedures”
(effective July 2015). QbD recommends us to perform
multivariate experiments by screening and scouting
of different variables using Design of Experiments
(DOE) approach. Screening and scouting can be
done on UPLC by using multiple buffers, solvents
and column chemistries.
The adoption of UPLC methods for various tests by
different regulators like US-FDA, EMEA as release
methods or alternative methods and adoption of
UPLC by EP and USP in their monographs (NF and
MC) clearly reflects the reason for the increase in
trend with respect to its implementation. Here are
some of the products having official UPLC methods
in USP- Glycopyrrolate, Tramadol HCl extended release
tablets, Ganoderma Lucidum, Sulindac, Aminolevulinic
acid, Schisandra Fruit, Almotriptan tablets. Reference
UPLC methods official in EP are Quetiapine fumarate
and Nevirapine. The recent revision of USP Chapter
<621> allows the conversion of HPLC methods to
UPLC without the need of complete validation.
Hence, Pharmaceutical companies can leverage
upon the new technologies to increase the
throughput efficiency and differentiate oneself in
this competitive world. To summarize, in order to
have a bigger and stronger impact in pharmaceutical
market, organizations need to adopt and implement
usage of innovative and differentiating technologies
like UPLC’s and new generation compact mass
detectors, which not only increases the productivity
but also reduces the risk of products failure.
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